Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations

European Journal of Surgical Oncology

Volumn 42, Issue 9, 2016, Pages 1378-1384

  Passot, G ^a   Chun, Y S ^a   Kopetz, S E ^a   Overman, M J ^a   Conrad, C ^a   Aloia, T A ^a   Vauthey, J N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Colorectal; Liver; Metastases; RAS

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; FEMALE; GENE MUTATION; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; ONCOGENE RAS; OVERALL SURVIVAL; PATIENT SELECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; GENETICS; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METASTASIS RESECTION; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; PROGNOSIS; RAS PROTEINS; SURVIVAL RATE; YOUNG ADULT;

EID: 84991073539     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2016.02.249     Document Type: Article

References (32)

1. 1 Manfredi, S., Lepage, C., Hatem, C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244 (2006), 254–259.
2. 2 Gruenberger, B., Tamandl, D., Schueller, J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26 (2008), 1830–1835.
3. 3 Folprecht, G., Gruenberger, T., Bechstein, W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11 (2010), 38–47.
4. 4 Kopetz, S., Chang, G.J., Overman, M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27 (2009), 3677–3683.
5. 5 Cucchetti, A., Ferrero, A., Cescon, M., et al. Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol 22 (2015), 1908–1914.
6. 6 Adam, R., Pascal, G., Castaing, D., et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?. Ann Surg 240 (2004), 1052–1061.
7. 7 Brouquet, A., Overman, M.J., Kopetz, S., et al. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?. Cancer 117 (2011), 4484–4492.
8. 8 Brudvik, K.W., Kopetz, S.E., Li, L., et al. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102 (2015), 1175–1183.
9. 9 Blazer, D.G. 3rd, Kishi, Y., Maru, D.M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26 (2008), 5344–5351.
10. 10 Pawlik, T.M., Scoggins, C.R., Zorzi, D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241 (2005), 715–722.
11. 11 Vauthey, J.N., Zimmitti, G., Kopetz, S.E., et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258 (2013), 619–626.
12. 12 Kopetz, S., Vauthey, J.N., Perioperative chemotherapy for resectable hepatic metastases. Lancet 371 (2008), 963–965.
13. 13 Atreya, C.E., Corcoran, R.B., Kopetz, S., Expanded RAS: refining the patient population. J Clin Oncol 33 (2015), 682–685.
14. 14 Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000), 205–216.
15. 15 Shindoh, J., Loyer, E.M., Kopetz, S., et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30 (2012), 4566–4572.
16. 16 Chun, Y.S., Vauthey, J.N., Boonsirikamchai, P., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302 (2009), 2338–2344.
17. 17 Charnsangavej, C., Clary, B., Fong, Y., et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13 (2006), 1261–1268.
18. 18 Mise, Y., Kopetz, S., Mehran, R.J., et al. Is complete liver resection without resection of synchronous lung metastases justified?. Ann Surg Oncol 22 (2015), 1585–1592.
19. 19 Adams, R.B., Aloia, T.A., Loyer, E., et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) 15 (2013), 91–103.
20. 20 Brouquet, A., Abdalla, E.K., Kopetz, S., et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29 (2011), 1083–1090.
21. 21 Cunningham, D., Humblet, Y., Siena, S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004), 337–345.
22. 22 Kim, G.P., Sargent, D.J., Mahoney, M.R., et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 27 (2009), 2848–2854.
23. 23 Koopman, M., Antonini, N.F., Douma, J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007), 135–142.
24. 24 Seymour, M.T., Maughan, T.S., Ledermann, J.A., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007), 143–152.
25. 25 Tournigand, C., Andre, T., Achille, E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004), 229–237.
26. 26 Di Nicolantonio, F., Martini, M., Molinari, F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 (2008), 5705–5712.
27. 27 Mise, Y., Zimmitti, G., Shindoh, J., et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 22 (2014), 1585–1592.
28. 28 Italiano, A., Hostein, I., Soubeyran, I., et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 17 (2010), 1429–1434.
29. 29 Knijn, N., Mekenkamp, L.J., Klomp, M., et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 104 (2011), 1020–1026.
30. 30 Kawamoto, Y., Tsuchihara, K., Yoshino, T., et al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer 107 (2012), 340–344.
31. 31 Karoui, M., Penna, C., Amin-Hashem, M., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 (2006), 1–7.
32. 32 Zimmitti, G., Roses, R.E., Andreou, A., et al. Greater complexity of liver surgery is not associated with an increased incidence of liver-related complications except for bile leak: an experience with 2,628 consecutive resections. J Gastrointest Surg 17 (2013), 57–64.